β-Amyloid (25-35)
Based on 51 publication(s) in Google Scholar
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.48%
- CAS. Nr.: 131602-53-4
- Formel: C45H81N13O14S
- Molecular Weight:1060.27
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P1363A
β-Amyloid (1-42), humanAmyloid β Peptide -
HY-P1388
β-Amyloid (1-42), (rat/mouse)β-Amyloid (1-42) Peptide -
HY-B0015
PaclitaxelAntitumor Agent -
HY-18739
Phorbol 12-myristate 13-acetatePKC Activator -
HY-P1362
β-Amyloid (42-1), humanInactive Form of Aβ(1-42) -
HY-N0210
D-GalactoseEndogenous Metabolite -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-P5124
β-Amyloid peptide(16-20)Abeta Inhibitor -
HY-15763
ErastinFerroptosis Inducer -
HY-13453
BAY 11-7082IκBα/NF-κB Inhibitor -
HY-D0218
Thioflavin Tβ-amyloid Dye -
HY-K0301
Cell Counting Kit-8
Publications Citing Use of MedChemExpress (MCE) β-Amyloid (25-35)
More- J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
- Adv Sci (Weinh). 2026 Jul 6:e76480.
- Phytomedicine. 2026 Apr:153:157916. [Abstract]
- Phytomedicine. 2024 Dec:135:156041. [Abstract]
- ACS Sens. 2026 Jun 26;11(6):5047-5057. [Abstract]
- Acta Pharmacol Sin. 2026 Mar 19. [Abstract]
- Alzheimers Res Ther. 2025 May 15;17(1):104. [Abstract]
- Int J Biol Macromol. 2024 Aug 22;278(Pt 4):134972. [Abstract]
- Int J Nanomedicine. 2023 Nov 16:18:6797-6812. [Abstract]
- Phytother Res. 2023 Apr;37(4):1346-1365. [Abstract]
- Phytother Res. 2023 Feb;37(2):410-423. [Abstract]
- Am J Chin Med. 2025 Aug 30:1-32. [Abstract]
- J Ethnopharmacol. 2023 Sep 15:313:116550. [Abstract]
- J Ethnopharmacol. 2023 Aug 10:312:116455. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70771. [Abstract]
- Life Sci. 2026 Oct 1:402:124583.
- Inflammopharmacology. 2025 Dec 6. [Abstract]
- Inflammopharmacology. 2024 Dec;32(6):3745-3759. [Abstract]
- Food Biosci. 2024 Dec.
- Int Immunopharmacol. 2026 Feb 1:170:116097. [Abstract]
- Neuropharmacology. 2025 Dec 14:286:110808. [Abstract]
- Brain Res Bull. 2026 Jun 7:243:111972. [Abstract]
- Neurochem Res. 2025 Apr 4;50(2):135. [Abstract]
- Brain Res Bull. 2024 Sep:215:111004. [Abstract]
- Neurochem Res. 2021 Sep;46(9):2376-2386. [Abstract]
- BMC Complement Med Ther. 2025 Mar 7;25(1):94. [Abstract]
- Front Cell Neurosci. 2021 Mar 25;15:614556. [Abstract]
- FASEB J. 2026 Mar 31;40(6):e71654. [Abstract]
- Neurotox Res. 2026 Mar 19;44(2):12. [Abstract]
- Metab Brain Dis. 2024 Oct;39(7):1433-1445. [Abstract]
- Hum Exp Toxicol. 2021 Dec;40(12_suppl):S347-S358. [Abstract]
- J Integr Neurosci. 2023 Jul 26;22(4):105. [Abstract]
- Tissue Cell. 2026 Jul 29;104(Pt 1):103825.
- J Neurol Sci. 2020 Jun 15:413:116793. [Abstract]
- Fitoterapia. 2026 Apr:190:107162. [Abstract]
- Toxicol Res (Camb). 2023 Aug 7;12(5):756-764. [Abstract]
- Chem Biodivers. 2023 Jun;20(6):e202300430. [Abstract]
- Biomed Res Int. 2019 Apr 16:2019:4690280. [Abstract]
- J Mol Neurosci. 2020 Oct;70(10):1589-1597. [Abstract]
- Int J Neurosci. 2021 Feb;131(2):154-162. [Abstract]
- Lett Drug Des Discov. 2026 Jul 13.
- Eur J Inflamm. December 1, 2021.
- medRxiv. 2026 Jul 17:2026.07.14.26357774.
- medRxiv. 2026 Jul 16.
- chemRxiv. 2026 Apr 24.
- Res Sq. 2025 Oct 20.
- Research Square Preprint. 2024 Apr 25.
- Research Square Preprint. 2024 Jan 5.
- Cell Mol Biol (Noisy-le-grand). 2024 Jan 31;70(1):200-206. [Abstract]
- Research Square Preprint. 2023 May 22.
- J Biomater Tissue Eng. 2021, pp. 295-301(7).
Customer Validation & Images
-
Cell Imaging/Staining
-
Flow Cytometry
-
ELISA
-
WB
-
IF
Biologische Aktivität
Beschreibung
In Vitro
The amino acid sequence of Aβ(25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents the amino acid 25 and the last Met represents the amino acid 35. Amyloid beta-peptide(25-35) is also investigated in gel state for the first time. Comparative studies are also carried out using vibrational absorption and ECD. The conformational preference of Aβ(25-35) peptide film is also investigated using vibrational absorption and VCD spectroscopy[1].
Amyloid beta-peptide(25-35) induces apoptotic effects on isolated brain mitochondria and the redox state of methionine-35, plays a key role in the induction of programmed cellular death pathways and toxic events[2].
β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
1. Solid Aβ peptide is dissolved in cold hexafluoro-2-propanol (HFIP). The peptide is incubated at room temperature for at least 1 h to establish monomerization and randomization of structure.
2. The HFIP is removed by evaporation, and the resulting peptide is stored as a film at -20 or -80 °C.
3. The resulting film is dissolved in anhydrous DMSO at 5 mM and then dilutes into the appropriate concentration and buffer (serum- and phenol red-free culture medium) with vortexing.
4. Next, the solution is aged for 7 days at 37°C. The sample is then centrifuged at 14000g for 10 min at 4-8 °C; the soluble oligomers are in the supernatant. The supernatant is diluted 10-200-fold for experiments.
Methods vary depends on the downstream applications.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Induced Disease Models
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
β-Amyloid (25-35) can be used in animal modeling to create Alzheimer's disease models[5].
Administration: 3 μg/μl in 5 μl within 1.2 μl/min • i.c.v • once
(2) Drug is given by injection using a G27 gauge needle inserted to a depth of 3.8 mm with a Hamilton syringe.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 131602-53-4
-
Appearance Solid
-
Molecular Weight 1060.27
-
Formel C45H81N13O14S
-
Color White to off-white
-
Synonyms
Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35)
-
Sequence
Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met
-
Sequence Shortening
GSNKGAIIGLM
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * The compound is unstable in solutions, freshly prepared is recommended.
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
J Nanobiotechnology
A novel biomimetic nanovesicle containing caffeic acid-coupled carbon quantum dots for the the treatment of Alzheimer's disease via nasal administration. [Abstract]2024 Oct 19;22(1):642. PMID: 39425199
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
DCFH-DA probe fluorescence Images of different groups of BV2 cells induced by β-Amyloid (25-35)(Aβ; 10µM; 24 h) , scale bar =250 μm.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Flow cytometry detection of ROS in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Quantitative analysis of ELISA results for IL-1β, IL-6, TNF-α, and IL-10 in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Western blot analysis of IL-1β, IL-6, TNF-α, and IL-10 related pathological proteins in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Fluorescence images of IL-1β (I) and IL-6 (J) in different groups including β-Amyloid (25-35)(Aβ; 10µM; 24 h) of BV2 cells, scale bar = 50 μm.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Quantitative analysis of fluorescence curves for Thioflavin T (THT) detection of Aβ fiber aggregation in different groups including induction by β-Amyloid (25-35) (Aβ; 20 µM; 0-72 h) of BV2 cells.
β-Amyloid (25-35) purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2024 Oct 19;22(1):642. [Abstract]
Image of Annexin V-FITC apoptosis detection in different groups including β-Amyloid (25-35) (Aβ; 10 µM; 24 h) of SH-SY5Y cells.
-
-
Phytomedicine
Da-Bu-Yin-Wan rescues cognitive deficits in aging and Alzheimer's disease models by Wnt/β-catenin-dependent restoration of lysosomal acidification. [Abstract]2026 Apr:153:157916. PMID: 41662806 -
Phytomedicine
Jiawei Xionggui Decoction promotes meningeal lymphatic vessels clearance of β-amyloid by inhibiting arachidonic acid pathway. [Abstract]2024 Dec:135:156041. PMID: 39299091 -
ACS Sens
A Polarity-Sensitive Lipid Droplet Probe Reveals Aβ Species-Dependent Lipid Droplet Remodeling in Microglia. [Abstract]2026 Jun 26;11(6):5047-5057. PMID: 42263671 -
Acta Pharmacol Sin
Selective inhibition of monoamine oxidase B represents a therapeutic strategy for diabetic peripheral neuropathy. [Abstract]2026 Mar 19. PMID: 41857368 -
Alzheimers Res Ther
tRFAla-AGC-3-M8 attenuates neuroinflammation and neuronal damage in Alzheimer's disease via the EphA7-ERK1/2-p70S6K signaling pathway. [Abstract]2025 May 15;17(1):104. PMID: 40375351 -
Int J Biol Macromol
Chloride intracellular channel 4 blockade improves cognition in mice with Alzheimer's disease: CLIC4 protein expression and tau protein hyperphosphorylation. [Abstract]2024 Aug 22;278(Pt 4):134972. PMID: 39181373 -
Int J Nanomedicine
Functionalized Cerium Dioxide Nanoparticles with Antioxidative Neuroprotection for Alzheimer's Disease. [Abstract]2023 Nov 16:18:6797-6812. PMID: 38026525 -
Phytother Res
Neuroprotective effects of hawthorn leaf flavonoids in Aβ25-35 -induced Alzheimer's disease model. [Abstract]2023 Apr;37(4):1346-1365. PMID: 36447359 -
Phytother Res
3, 14, 19-Triacetyl Andrographolide alleviates the cognitive dysfunction of 3 × Tg-AD mice by inducing initiation and promoting degradation process of autophagy. [Abstract]2023 Feb;37(2):410-423. PMID: 36114804 -
Am J Chin Med
Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]2025 Aug 30:1-32. PMID: 40884807 -
J Ethnopharmacol
Neuroprotective effects of PRG on Aβ25-35-induced cytotoxicity through activation of the ERK1/2 signaling pathway. [Abstract]2023 Sep 15:313:116550. PMID: 37120057 -
J Ethnopharmacol
Loganin alleviated cognitive impairment in 3×Tg-AD mice through promoting mitophagy mediated by optineurin. [Abstract]2023 Aug 10:312:116455. PMID: 37019163 -
CNS Neurosci Ther
β-Asarone Attenuates Neuroinflammation of Alzheimer's Disease by Activating Autophagy and Suppressing NLRP3 Inflammasome Assembly. [Abstract]2026 Feb;32(2):e70771. PMID: 41635250 -
-
Inflammopharmacology
Neuroprotective effects of SRS11-92 against oxidative stress-induced senescence via Nrf2/HO-1/NF-κB in Alzheimer's disease models. [Abstract]2025 Dec 6. PMID: 41350486 -
Inflammopharmacology
A medicine and food homology formula prevents cognitive deficits by inhibiting neuroinflammation and oxidative stress via activating AEA-Trpv1-Nrf2 pathway. [Abstract]2024 Dec;32(6):3745-3759. PMID: 39305407 -
-
Int Immunopharmacol
Thymosin β4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo 5 × FAD mice: A potential therapy for memory improvement in Alzheimer's disease. [Abstract]2026 Feb 1:170:116097. PMID: 41443105 -
Neuropharmacology
Cftr nominates a novel therapeutic target for Alzheimer's disease: Evidence from integrative omics and in vitro validation. [Abstract]2025 Dec 14:286:110808. PMID: 41401902 -
Brain Res Bull
Unveiling the multi-target mechanisms of Zuo Gui Wan in Alzheimer's disease: An integrated study combining network pharmacology, Mendelian Randomization, and molecular docking. [Abstract]2026 Jun 7:243:111972. PMID: 42259474 -
Neurochem Res
Targeting UAF1 Alleviate Neurotoxicity by Inhibiting APP/NLRP3 Axis-Mediated Pyroptosis and Apoptosis. [Abstract]2025 Apr 4;50(2):135. PMID: 40183841 -
Brain Res Bull
Hsa_circ_0049472 contributed to amyloid-beta peptide-induced neurotoxicity, apoptosis and inflammation via regulating PI3K-AKT signaling pathway by interacting with miR-22-3p/ZNF217 axis. [Abstract]2024 Sep:215:111004. PMID: 38852653 -
Neurochem Res
SRY-Box 21 Antisense RNA 1 Knockdown Diminishes Amyloid Beta25-35-Induced Neuronal Damage by miR-132/PI3K/AKT Pathway. [Abstract]2021 Sep;46(9):2376-2386. PMID: 34146195 -
BMC Complement Med Ther
Network pharmacology mechanism of Rosmarinus officinalis L.(Rosemary) to improve cell viability and reduces apoptosis in treating Alzheimer's disease. [Abstract]2025 Mar 7;25(1):94. PMID: 40055645 -
Front Cell Neurosci
IRE1α-XBP1 Affects the Mitochondrial Function of Aβ25-35-Treated SH-SY5Y Cells by Regulating Mitochondria-Associated Endoplasmic Reticulum Membranes. [Abstract]2021 Mar 25;15:614556. PMID: 33841100 -
FASEB J
Hypermethylation of FGF13 Reduces Microtubule Stability via Interaction With TUBB2A to Promote Mitochondrial Dysfunction in Alzheimer's Disease. [Abstract]2026 Mar 31;40(6):e71654. PMID: 41808420 -
Neurotox Res
Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]2026 Mar 19;44(2):12. PMID: 41854817 -
Metab Brain Dis
Integrative analysis reveals key lysosomal genes as potential therapeutic targets in Alzheimer's disease. [Abstract]2024 Oct;39(7):1433-1445. PMID: 39150655 -
Hum Exp Toxicol
Notoginsenoside R2 reduces A β 25-35-induced neuronal apoptosis and inflammation via miR-27a/SOX8/ β-catenin axis. [Abstract]2021 Dec;40(12_suppl):S347-S358. PMID: 34533063 -
J Integr Neurosci
Bioinformatics and Experimental Identification of circ_0001535 Associated with Diagnosis and Development of Alzheimer's Disease. [Abstract]2023 Jul 26;22(4):105. PMID: 37519165 -
-
J Neurol Sci
2020 Jun 15:413:116793. PMID: 32251872 -
Fitoterapia
Exploring the effect of Kaixin San on Alzheimer's disease by regulating the Keap1/Nrf2/GPX4 signaling pathway to inhibit ferroptosis based on metabolomics and gut microbiota analysis. [Abstract]2026 Apr:190:107162. PMID: 41796868 -
Toxicol Res (Camb)
Scorpion venom heat-resistant peptide alleviates mitochondrial dynamics imbalance induced by PM2.5 exposure by downregulating the PGC-1α/SIRT3 signaling pathway. [Abstract]2023 Aug 7;12(5):756-764. PMID: 37915494 -
Chem Biodivers
Study on Calceolarioside A anti-Aβ25-35-induced Damage in SH-SY5Y Cells by Atomic Force Microscopy. [Abstract]2023 Jun;20(6):e202300430. PMID: 37166365 -
Biomed Res Int
Glutamine Improves Oxidative Stress through the Wnt3a/ β-Catenin Signaling Pathway in Alzheimer's Disease In Vitro and In Vivo. [Abstract]2019 Apr 16:2019:4690280. PMID: 31119171 -
J Mol Neurosci
MicroRNA-107 Ameliorates Damage in a Cell Model of Alzheimer's Disease by Mediating the FGF7/FGFR2/PI3K/Akt Pathway. [Abstract]2020 Oct;70(10):1589-1597. PMID: 32472396 -
Int J Neurosci
Vascular endothelial growth factor alleviates mitochondrial dysfunction and suppression of mitochondrial biogenesis in models of Alzheimer's disease. [Abstract]2021 Feb;131(2):154-162. PMID: 32083964 -
-
-
-
-
-
-
-
-
Cell Mol Biol (Noisy-le-grand)
Up-regulation of lncRNA WT1-AS ameliorates Aβ-stimulated neuronal injury through modulation of miR-186-5p/CCND2 axis in Alzheimer's disease. [Abstract]2024 Jan 31;70(1):200-206. PMID: 38372094 -
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (23.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 3.33 mg/mL (3.14 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Neurotoxicity Study
This protocol assesses in vitro neurotoxicity by combining neuronal viability, mitochondrial/metabolic activity, neurite outgrowth, and optional neuronal network function readouts. Calcein-AM or resazurin/PrestoBlue readouts estimate viable or metabolically active cells; βIII-tubulin immunofluorescence detects neuronal morphology and neurite networks; TMRE detects mitochondrial membrane potential; and MEA recordings detect functional changes in neuronal network activity.
-
Amyloid: Congo Red Amyloid Staining
Congo red amyloid staining is a histochemical method used to detect extracellular amyloid deposits in tissue sections based on the affinity of Congo red dye for β-pleated sheet-rich protein aggregates. When bound to amyloid, Congo red produces characteristic apple-green birefringence under polarized light microscopy, which is widely regarded as a diagnostic feature of amyloid deposition in histopathology. The diagnostic principle relies on the combination of dye binding (congophilia) and optical anisotropy under polarized illumination, which distinguishes amyloid from most non-amyloid eosinophilic extracellular deposits in routine histological evaluation. Amyloid identification by Congo red staining remains a cornerstone in diagnostic pathology despite the availability of adjunct methods such as immunohistochemistry and mass spectrometry, particularly because of its ability to localize deposits directly within tissue architecture. The specificity of Congo red-positive deposits is incre
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Reinheit & Dokumentation
-
Data Sheet (284 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. D'Ursi AM, et al. Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem. 2004 Aug 12;47(17):4231-8. [Content Brief]
[2]. Clementi ME, et al. Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death throughapoptotic signals: Role of the redox state of methionine-35. FEBS Lett. 2005 May 23;579(13):2913-8. [Content Brief]
[3]. Liu M, et al. Cognitive improvement of compound danshen in an Aβ25-35 peptide-induced rat model of Alzheimer's disease. BMC Complement Altern Med. 2015 Oct 23;15:382. [Content Brief]
[4]. Patel NS, et al. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid. 2008;15(1):5-19. [Content Brief]
[5]. Julia Fedotova, et al. Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25–35)-induced amnesia. Phytomedicine. 2012 Mar 15;19(5):451-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9432 mL | 4.7158 mL | 9.4316 mL | 23.5789 mL |
| DMSO | 5 mM | 0.1886 mL | 0.9432 mL | 1.8863 mL | 4.7158 mL |
| 10 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL | 2.3579 mL | |
| 15 mM | 0.0629 mL | 0.3144 mL | 0.6288 mL | 1.5719 mL | |
| 20 mM | 0.0472 mL | 0.2358 mL | 0.4716 mL | 1.1789 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
β-Amyloid (25-35) Related Classifications
HY-P0128 Related Classifications
Powered by Bioz